R&D | April 12, 2026
Touchlight and SVF partner to advance next-gen Hepatitis B/D vaccine development
The company says the platform offers improved manufacturability and functional advantages
The company says the platform offers improved manufacturability and functional advantages
These surgeries involve no bone cuts, minimal surgical trauma, smaller incisions and significantly reduced blood loss
The approval now covers procedures using 10-14F inner diameter and up to 17F outer diameter procedural sheaths
The dual expansion simplifies transcriptomics workflows by combining faster regional turnaround with easier sample logistics
The new single-pill therapy combines cilnidipine, telmisartan and metoprolol, bringing together three established antihypertensive agents with complementary mechanisms
Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size
Immediate U.S. launch planned for dapagliflozin-metformin ER tablets; addressable market estimated at $514 millionannually
Immediate opportunity in the $10.2 billion U.S. market as the diabetes therapy will be manufactured at Zydus’ SEZ Ahmedabad facility
Final approval for diabetes and heart-failure drug opens access to a $10.5 billion US market opportunity, with shared exclusivity benefits.
Company leadership is framing the move as transformational.
Subscribe To Our Newsletter & Stay Updated
